In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming

Abstract

SUMMARY Aging is the major risk factor for many human diseases. In vitro studies have demonstrated that cellular reprogramming to pluripotency reverses cellular age, but alteration of the aging process through reprogramming has not been directly demonstrated in vivo. Here, we report that partial reprogramming by short-term cyclic expression of Oct4, Sox2, Klf4, and c-Myc (OSKM) ameliorates cellular and physiological hallmarks of aging and prolongs lifespan in a mouse model of premature aging. Similarly, expression of OSKM in vivo improves recovery from metabolic disease and muscle injury in older wild-type mice. The amelioration of age-associated phenotypes by epigenetic remodeling during cellular reprogramming highlights the role of epigenetic dysregulation as a driver of mammalian aging. Establishing in vivo platforms to modulate age-associated epigenetic marks may provide further insights into the biology of aging.

Untitled

“…Here, we underscored the potential of therapeutic elimination of senescent cells, for instance by FOXO4-DRI. In addition, exciting developments were recently reported in the field of stem cell biology, where it was shown that transient expression of the Yamanaka stem cell factors can promote tissue rejuvenation [7]. This is not yet therapeutically applicable, but most likely this will only be a matter of time.…”

Treating multiple antiaging pathways improves health markers in open label clinical study

“…As a comparison to the placebo-controlled clinical trial with the statin Atovastatin (Atorvas Fig. 3), 6 weeks of treatment at 10 mg/day dose increases HDL Cholesterol by 3.5%, which is not significantly different from the placebo increases in HDL Cholesterol of 2.3% [70]. Fig.…”

“…We also identified the subset of nutraceuticals that have little or no known side effects. Finally, we focused on stem cell function as a critical factor in rejuvenation [4][5][6] by screening candidate longevity nutraceuticals for their effectiveness in stimulating and/or maintaining adult stem cell growth in human tissue culture screens. As we detail below, the final 10 herbal extracts in SC100+ provide a diverse set of bioactive compounds, which appear to act on many of the critical health and longevity pathways.…”

Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?

“…Also, low-caloric diets, that can extend the approximate 2-year lifespan of rodents by more than 40%, extend the approximate 6-year lifespan of primates by more than 50% (see Pifferi et al 2018), without observed sign of physical nor mental health deterioration. The graft of bio-printed organs (see Ravnic et al 2017;and Mir and Nakamura 2017) and the in vivo degradation of old tissues that the body then naturally replaces by younger tissue (see Fahy 2003;Ocampo et al 2016;Mosteiro et al 2016;and Mendelsohn et al 2017) are already being tested in specific clinical settings. The latter advances show that science is not only on its way to slow down human aging but also to restore youthful characteristics to the body once old.…”